Tactile Medical (Nasdaq: TCMD) announced that management will present at the William Blair 46th Annual Growth Stock Conference at the Loews Hotel in Chicago from June 2-4, 2026. The company’s presentation is scheduled for Tuesday, June 2, at 9:20 a.m. CT.
A live audio webcast and replay will be available in the “Events & Webcasts” section of Tactile Medical’s investor relations website. Tactile Medical develops at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – TCMD
+3.18%
+3.18%Session close to close
In the May 21 session, TCMD gained 3.18%, reflecting a moderate positive market reaction.
This announcement highlights TCMD’s participation in the William Blair 46th Annual Growth Stock Conf...
Analysis
This announcement highlights TCMD’s participation in the William Blair 46th Annual Growth Stock Conference from June 2–4, 2026, with a presentation on June 2 at 9:20 a.m. CT. The event centers on investor outreach, complementing earlier milestones such as recent earnings, guidance, and the LymphaTech acquisition. Investors can track management’s commentary via the webcast archive and watch for any subsequent disclosures or guidance changes following the conference.
Key Figures
Conference dates:June 2–4, 2026Presentation date:June 2, 2026Presentation time:9:20 a.m. Central Time+1 more
Acquired LymphaTech to add 3D measurement platform to lymphedema portfolio.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent fundamentally positive announcements (earnings, acquisition, board enhancement) have generally coincided with positive next-day price reactions.
Recent Company History
Over the last few months, TCMD reported strong growth, with Q4 2025 and Q1 2026 earnings both showing revenue expansion and higher margins, and the stock reacting positively (up to 17.83%). The company also acquired LymphaTech on February 17, 2026, which shared the same strong positive price reaction. A new director appointment on March 9, 2026 saw a modest gain, while a routine earnings date announcement in April drew a small pullback. Today’s William Blair conference appearance fits the pattern of ongoing investor engagement rather than a major new catalyst.
Key Terms
webcast, investor relations, lymphedema, lipedema, +2 more
6 terms
webcasttechnical
"A live audio webcast of the presentation will be accessible under the “Events"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
investor relationsfinancial
"section of the Company's investor relations website at http://investors.tactile"
Investor relations is the communication process between a company and its current or potential investors. It involves sharing information about the company's performance, strategies, and outlook to help investors make informed decisions. Effective investor relations build trust and transparency, similar to a clear conversation between a business and someone considering investing, ensuring both parties understand each other's interests and expectations.
lymphedemamedical
"conditions including lymphedema, lipedema, chronic venous insufficiency and"
Lymphedema is a chronic swelling that happens when the body’s fluid-draining network can’t move fluid away from tissues, causing persistent puffiness, heaviness and sometimes skin changes. Investors pay attention because it represents a steady demand for diagnostics, drugs, devices and long-term care—think of it like a clogged drain that creates ongoing repair and maintenance needs, so new treatments or devices can shift patient outcomes and company revenue for years.
lipedemamedical
"conditions including lymphedema, lipedema, chronic venous insufficiency and"
Lipedema is a chronic condition where fat deposits build up unevenly under the skin—usually in the legs and sometimes the arms—causing swelling, tenderness and reduced mobility; it is often mistaken for ordinary weight gain. For investors, it matters because the condition creates sustained demand for specialized diagnostics, non‑surgical therapies, compression garments and surgical treatments, as well as ongoing care and reimbursement considerations, making it a distinct market opportunity in medical devices and therapies.
chronic venous insufficiencymedical
"including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary"
A long-term condition in which the one-way valves in leg veins do not work properly, causing blood to pool, swelling, pain, skin changes or ulcers; think of it as a plumbing problem where backflow wears out pipes and fixtures. Investors care because it is a common, chronic market with ongoing demand for treatments, devices and wound-care products, and outcomes depend on clinical data, regulatory approvals and reimbursement decisions that affect revenue streams.
chronic pulmonary diseasemedical
"lipedema, chronic venous insufficiency and chronic pulmonary disease by helping"
A long-term lung condition that makes breathing harder by narrowing airways or damaging lung tissue, often causing coughing, shortness of breath and reduced exercise ability; think of it as a car with a partially clogged air filter that lowers performance over time. It matters to investors because the condition drives demand for medicines, devices, hospital care and clinical trials, so changes in treatment approvals, market size, or reimbursement can directly affect company revenues and healthcare costs.
MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the William Blair 46th Annual Growth Stock Conference, which is being held at the Loews Hotel in Chicago, IL, from June 2-4, 2026. Management will present on Tuesday, June 2, at 9:20 a.m. Central Time.
A live audio webcast of the presentation will be accessible under the “Events & Webcasts” section of the Company's investor relations website at http://investors.tactilemedical.com. An archive of the webcast will be available for replay following the conference.
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
When will Tactile Medical (TCMD) present at the William Blair 46th Annual Growth Stock Conference?
Tactile Medical will present on Tuesday, June 2, 2026, at 9:20 a.m. Central Time. The conference runs June 2-4, 2026, at the Loews Hotel in Chicago, offering investors access to management’s update.
How can investors access Tactile Medical’s (TCMD) William Blair conference webcast?
Investors can access a live audio webcast of Tactile Medical’s presentation in the “Events & Webcasts” section of its investor relations website. According to the company, an archived replay will also be available after the conference.
What is the William Blair 46th Annual Growth Stock Conference participation by Tactile Medical (TCMD)?
Tactile Medical announced that management will participate in the William Blair 46th Annual Growth Stock Conference. The event takes place June 2-4, 2026, in Chicago, with the company presenting on June 2 at 9:20 a.m. CT.
What does Tactile Medical (TCMD) do for patients with chronic conditions?
Tactile Medical develops and markets at-home therapies for chronic conditions like lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. According to the company, these therapies aim to help patients live better and manage care at home.
How does Tactile Medical (TCMD) work with clinicians to support its therapies?
Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness and increase access to care. According to the company, this collaboration also seeks to reduce overall healthcare costs and improve quality of life for tens of thousands of patients each year.
Where can investors direct inquiries about Tactile Medical (TCMD) around the June 2026 conference?
Investor inquiries for Tactile Medical can be directed to the Gilmartin Group contact, Sam Bentzinger, via the investorrelations@tactilemedical.com email address. This contact is provided for questions related to investor relations and conference participation.
